Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | dihydrofolate reductase | 0.0043 | 0.219 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0028 | 0.1058 | 0.1058 |
Echinococcus granulosus | intermediate filament protein | 0.0028 | 0.1058 | 0.1091 |
Brugia malayi | intermediate filament protein | 0.0028 | 0.1058 | 0.096 |
Brugia malayi | hypothetical protein | 0.005 | 0.272 | 0.264 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0149 | 0.9981 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0106 | 0.6804 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 0.0043 | 0.219 | 0.1267 |
Brugia malayi | thymidylate synthase | 0.0106 | 0.6804 | 0.6769 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0106 | 0.6804 | 0.6426 |
Echinococcus multilocularis | lamin | 0.0028 | 0.1058 | 0.1058 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0106 | 0.6804 | 1 |
Mycobacterium tuberculosis | Hypothetical protein | 0.005 | 0.272 | 0.1148 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.0043 | 0.219 | 0.219 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0044 | 0.2244 | 0.2316 |
Mycobacterium ulcerans | thymidylate synthase | 0.0106 | 0.6804 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0028 | 0.1058 | 0.1058 |
Brugia malayi | Dihydrofolate reductase | 0.0043 | 0.219 | 0.2105 |
Echinococcus multilocularis | dihydrofolate reductase | 0.0043 | 0.219 | 0.219 |
Entamoeba histolytica | acetyltransferase, GNAT family | 0.004 | 0.1975 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.1058 | 0.1058 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0015 | 0.0109 | 0.0109 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0149 | 0.9981 | 1 |
Loa Loa (eye worm) | acetyltransferase | 0.0149 | 1 | 1 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0149 | 0.9981 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0149 | 0.9981 | 1 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0149 | 0.9981 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0028 | 0.1058 | 0.1091 |
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0149 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0028 | 0.1058 | 0.096 |
Trichomonas vaginalis | conserved hypothetical protein | 0.005 | 0.272 | 1 |
Echinococcus granulosus | lamin | 0.0028 | 0.1058 | 0.1091 |
Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0149 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.102 | 0.102 |
Echinococcus multilocularis | musashi | 0.0028 | 0.1058 | 0.1058 |
Loa Loa (eye worm) | thymidylate synthase | 0.0106 | 0.6804 | 0.6804 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0028 | 0.1058 | 0.1058 |
Brugia malayi | dihydrofolate reductase family protein | 0.0043 | 0.219 | 0.2105 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0149 | 0.9981 | 1 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0145 | 0.9692 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.0043 | 0.219 | 0.226 |
Echinococcus multilocularis | thymidylate synthase | 0.0106 | 0.6804 | 0.6804 |
Onchocerca volvulus | 0.0106 | 0.6804 | 1 | |
Echinococcus granulosus | thymidylate synthase | 0.0106 | 0.6804 | 0.702 |
Giardia lamblia | Histone acetyltransferase GCN5 | 0.004 | 0.1975 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.